Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $11.00.

Several research firms recently commented on EVAX. Wall Street Zen cut Evaxion A/S from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Evaxion A/S in a research report on Friday, April 24th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Evaxion A/S in a research note on Thursday, June 11th.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in EVAX. Rathbones Group PLC purchased a new stake in Evaxion A/S in the first quarter worth approximately $170,000. Renaissance Technologies LLC purchased a new stake in Evaxion A/S during the 1st quarter valued at $146,000. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Evaxion A/S during the 1st quarter valued at $112,000. SmartHarvest Portfolios LLC bought a new position in shares of Evaxion A/S during the 4th quarter valued at $72,000. Finally, Northwestern Mutual Wealth Management Co. purchased a new position in shares of Evaxion A/S in the 4th quarter worth $38,000. 11.04% of the stock is owned by hedge funds and other institutional investors.

Evaxion A/S Stock Performance

Shares of EVAX opened at $3.25 on Thursday. The company has a market cap of $27.11 million, a price-to-earnings ratio of -2.21 and a beta of 0.26. The business’s fifty day simple moving average is $3.75 and its two-hundred day simple moving average is $3.90. Evaxion A/S has a 12 month low of $2.41 and a 12 month high of $12.15. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41.

Evaxion A/S (NASDAQ:EVAX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.43). Research analysts anticipate that Evaxion A/S will post -0.5 earnings per share for the current fiscal year.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.